Pharmaceuticals & Life Sciences

Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (Nasdaq: VERV), a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, announce a definitive agreement for Lilly to acquire Verve. Verve is developing a pipeline of gene editing medicines designed to address the drivers of atherosclerotic cardiovascular disease (ASCVD) through treatments that may only

Crescent Biopharma, Inc. (“Crescent” or the “Company”), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, announces the completion of its previously announced merger with GlycoMimetics, Inc. (“GlycoMimetics”). The combined company will operate under the name Crescent Biopharma, Inc., and its shares are expected to begin trading on the

Endo, Inc. (“Endo” or the “Company”) (OTCQX: NDOI) today announced that it has completed the previously announced divestiture of its International Pharmaceuticals business, primarily operated through Canada-based specialty pharmaceutical company Paladin Pharma Inc., to Knight Therapeutics Inc. Total cash consideration for the sale is up to approximately $105 million, consisting of approximately $79 million paid

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) and Sage Therapeutics, Inc. (Nasdaq: SAGE), announce a definitive agreement for Supernus to acquire Sage through a tender offer for $8.50 per share in cash (or an aggregate of approximately $561 million), payable at closing, plus one non-tradable contingent value right (CVR) collectively worth up to $3.50 per share in